Abstract:Abstract: The corona virus disease 2019 (COVID-19) is spreading all over the world. The current clinical treatment is dependent on old drugs. However, the pharmacokinetic parameters of all these drugs in COVID-19 treatment are very limited, and furthermore, there are some therapeutic factors (such as hemodialysis, and extracorporeal membrane oxygenation (ECMO)) affecting pharmacokinetic parameters. It is necessary to perform therapeutic drug monitoring (TDM) to improve clinical efficacy and decrease drug adverse reactions. In this work, we reviewed the TDM development of hydroxychloroquine, teicoplanin, arbidol, Klitsch (lopinavir/ritonavir, LPV/RTV), and vancomycin used in COVID-19 patients, including the TDM progress of these drugs in other diseases, concentration detection methods (mainly liquid chromatograph tandem mass spec-trometry), therapeutic window range, and the TDM development of these drugs in COVID-19 patients. This review may provide methodological support for TDM research, and provide theoretical basis for individuali-zed medication of COVID-19.
引用本文:
邢亚茹, 李迎迎, 尹 林, 石慧春, 卢洪洲, 张丽军. 新型冠状病毒肺炎治疗药物监测研究进展[J]. 生命科学研究, 2020, 24(3): 173-179.
XING Ya-ru, LI Ying-ying, YIN Lin, SHI Hui-chun, LU Hong-zhou, ZHANG Li-jun. Progress in Therapeutic Drug Monitoring of 2019 Novel Coronavirus Pneumonia. Life Science Research, 2020, 24(3): 173-179.